1 BTC
=
- USD
Sana Biotechnology, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Sana Biotechnology, Inc. Common Stock
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
Market Statistics
Trading Metrics
How to Buy SANA
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy SANA
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesKailera Therapeutics completed the largest biotech IPO since 2021, raising $625 million at $16 per share. The company is developing GLP-1-based obesity treatments, with its lead candidate ribupatide in Phase 3 trials. Kailera enters a competitive $200 billion obesity market dominated by Eli Lilly and Novo Nordisk, with promising early data showing up to 12.1% weight loss in oral formulation trials.
U.S. stock futures rose on Tuesday following Monday's rally, with major indices trading higher. Vice President JD Vance signaled potential progress in Iran nuclear talks if Tehran meets U.S. demands. Investors await March producer price index data. Key movers include Sana Biotechnology surging 20% on Mayo Clinic collaboration, ChargePoint jumping 6.63% on insider buying, and Chevron declining despite a Venezuela oil production agreement. Professor Jeremy Siegel warns of near-term market caution due to rising oil prices and money growth concerns.
Sana Biotechnology published research in Nature Biotechnology demonstrating successful in vivo gene editing of human hematopoietic stem cells using fusogen technology, potentially transforming treatment for diseases like sickle cell and beta thalassemia without conditioning chemotherapy.
